| Published June 14, 2021

Status report Cereno Scientific – Expanded potential in cardiovascular disease

Cardiovascular diseases are the leading cause of death in the world and the need for better treatments is great. Swedish biotechnology company Cereno Scientific is developing new treatments for both common and rare cardiovascular diseases and will initiate a phase II study with its lead candidate CS1 in September this year. In 2021, the company has strengthened its team, its IP position and has also expanded its portfolio with two development programs in close collaboration with the University of Michigan. BioStock has now published a status report that can be downloaded below.

Download the status report on Cereno Scientific below.

Disclaimer

This is a status report prepared by BioStock on behalf of the analyzed Company. BioStock's remuneration for the analysis has been determined in advance and the remuneration is independent of the content and conclusions of the analysis. The content of this report is based on public information obtained through its own research and sources such as financial reports, the Company's website, public presentations and via contact with the Company's representatives. The information about the Company has been fact-checked and approved for publication by the Company. The analysis contains subjective assessments of the future which should be considered to entail uncertainty. Any valuations of the Company, products and market have been carried out by BioStock's analysts. The analyst does not own shares in the Company. This report should not be considered a recommendation or invitation to invest in the Company and should not be interpreted as financial advice. BioStock cannot guarantee that the conclusions presented in the report will be fulfilled. BioStock cannot be held liable for any direct or indirect damages caused by decisions made based on information in this status report. BioStock is not under the supervision of the Swedish Financial Supervisory Authority and therefore does not have to follow the rules that otherwise apply to research firms that are under the supervision of the Swedish Financial Supervisory Authority.